KRAS and colorectal carcinoma: The data for the CRC subgroup revealed a confirmed response in 29.1% of patients, with a median PFS of 5.6 months.202,227 It is being tested as a standalone drug and in combination with other medications, such as monoclonal antibodies, kinase inhibitors, and SHP2 inhibitors, for patients with advanced KRAS G12C-mutant solid cancers.221 The most common adverse effects include nausea (74%), diarrhea (61%), and vomiting (58%).175